Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology and Medical Oncologist at Angeles del Carmen Hospital, shared a post on X:
“Emerging landscape of KRAS inhibitors in cancer treatment. RAS alterations occur in ~20% of cancers. KRAS G12C inhibitors validated direct RAS targeting, but resistance limits durability. Next-generation strategies include RAS(ON), pan-KRAS/pan-RAS, non-G12C allele-specific inhibitors, and degraders. Can broader inhibition improve outcomes without excess toxicity? ”
Title: Emerging landscape of KRAS inhibitors in cancer treatment
Authors: Jakob M. Riedl, Hiroyuki Matsubara, Reid McNeil, Parasvi S. Patel, Ferran Fece de la Cruz, Doga C. Gulhan, Ryan B. Corcoran.
Other articles featuring Diego A. Díaz-García on OncoDaily.
